Dimerix Limited · ASX:DXB
Dimerix — Investor Presentation (April 2026)
26 slides from Dimerix's investor presentation, Apr 28, 2026
Slide 1: Dimerix Releases Investor Presentation & Video Recording
For Immediate Release DIMERIX RELEASES INVESTOR PRESENTATION & VIDEO RECORDING MELBOURNE, Australia, 28 April 2026: Dimerix Limited (ASX: DXB) (“Dimerix” or the “Company”), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, is pleased to release an updated investor presenta
Slide 2: About Dimerix, DMX-200 and FSGS
For further information, please visit our website at www.dimerix.com or contact: Dr Nina Webster Jane Lowe Dimerix Limited IR Department Chief Executive Officer & Managing Director Tel: +61 411 117 774 Tel: +61 1300 813 321 E: jane.lowe@irdepartment.com.au E: investor@dimerix.com Follow Dimerix on L
Slide 3: References
patent protection, future capital needs or other general risks or factors, along with those factors outlined in the most recent Dimerix Limited Annual Report. References 1 ASX releases: 14 December 2015, 21 November 2018, 07 June 2021, 30 September 2025 2 Nephcure FSGS Facts (https://nephcure.org/)
Slide 4: Developing new therapies to treat inflammatory causes of kidney disease
For personal use only Developing new therapies to treat inflammatory causes of kidney disease with unmet clinical needs Investor Presentation April 2026 Authorised for lodgement by the Board of the Company
Slide 5: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. For personal use only Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Dimerix can give no assurance that th
Slide 6: Phase 3 Global Opportunity
Phase 3 Global Opportunity For personal use only Phase 3 trial Reduced risk FSGS indication Orphan drug 4 commercial up to $1.4 billion recruitment Proteinuria endpoint passed blinded is a rare disease designations partners in total complete in interim (futility) assessment1 that causes scarring reg
Slide 7: What is FSGS? Cycle of damage in glomerular diseases
Cycle of damage in glomerular diseases What is FSGS? Existing blood pressure medication For personal use only Glomeruli exposed to stress from high blood pressure DMX-200 Focal = some 1 Segmental = sections High blood pressure causes hyperfiltration Glomerulo = of the kidney filtering units within f
Slide 8: Interpreting proteinuria as a surrogate endpoint
Interpreting proteinuria as a surrogate endpoint Proteinuria is the quantity of protein in the urine Proteinuria as a predictor of kidney disease3 For personal use only A healthy kidney is a good filter and allows little to no protein into Dip test uPCR g/g the urine1 NORMAL Neg <0.13 normal Inside
Slide 9: Endpoint selection
endpoint selection For personal use only Step 1 Step 2 Step 3 Step 4 PARASOL FSGS Seek FDA alignment on Blinded review to To maximise the working group 12- endpoints and process assess endpoint likelihood of a month data analysis for blinded review, power: ACTION3 successful study received1 ACTION3
Slide 10: Proteinuria as ACTION3 primary endpoint
Proteinuria as ACTION3 primary endpoint For personal use only ACTION3 Phase 3 futility analysis demonstrated DMX-200 was FDA agreed that proteinuria is an Collectively, the PARASOL Blinded review confirmed performing better than placebo appropriate endpoint DMX-200 working group,6 the National ACTIO
Slide 11: DMX-200: Phase 2 met primary endpoint
DMX-200: Phase 2 met primary endpoint Clinically encouraging outcomes achieved for patients,1,2 with no safety concerns noted3 For personal use only Average reduction of 17% in proteinuria after 16 weeks treatment on DMX-200 versus placebo3 “Any reduction in proteinuria could yield years of preserve
Slide 12: Phase 3 ACTION3 clinical trial
European Renal Association Posters 2025 phase 3 clinical trial A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB (n=≥286) For personal use only Background Phase 3 Trial Timeline Open Label Extension Successful inter
Slide 13: Adult patient recruitment by territory
Adult patient recruitment by territory Trial designed for potential Recruitment approval globally For personal use only completed (adult population)1 333 Adult patients recruited, randomised and dosed (target ≥286)2 6 Paediatric patients recruited, randomised and dosed2 Latin America Asia Pacific US
Slide 14: Competitive/complementary trial landscape in FSGS
Competitive/complementary trial landscape in FSGS Low competition in inflammatory treatment options, large unmet medical need For personal use only DMX-200 is the only inflammatory modulator in development specifically for FSGS DMX-200 has potential for use in conjunction with other drugs in develop
Slide 15: Summary of licensing deals for DMX-200 to date
Summary of licensing deals for DMX-200 to date Licensing deals collectively Dimerix has successfully partnered DMX-200 across key markets valued up to For personal use only 1 2 3 4 ~AU$1.4 billion in total upfront and potential milestone fees plus royalties1 United States EU, CA, AU, NZ GCC, Iraq Ja
Slide 16: DMX-200 substantially de-risked Phase 3 renal asset
DMX-200 substantially de-risked Phase 3 renal asset Blinded review Proteinuria endpoint Commercial validation: Study fully recruited: For personal use only confirmed study reduced risk: passed 4 commercial partners fixed timelines to full remains appropriately blinded interim (futility) across key t
Slide 17: Growth strategy
Growth strategy For personal use only Deliver ACTION3 Phase 3 Expand global commercial Advance pipeline development clinical trial partnerships • Identify and progress new assets in • Ensure drug supply continuity and • Build on existing licensing agreements renal and/or rare disease indications pat
Slide 18: Corporate overview
Corporate overview S H A R E P R I C E Ticker Symbol ASX: DXB For personal use only Cash Balance (Dec25) $38.5 million Market Capitalisation1 $235 million Share price1 $0.39 Total ordinary shares on issue1 600,396,776 Average Daily Liquidity by value for $0.49 million past 30 trading days2 Research
Slide 19: ESG Statement
(ASX:DXB) For personal use only W E L L P O S I T I O N E D TO D E L I V E R AGA I N ST ST R AT EG I C P L A N ESG Statement Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The
Slide 20: DMX-200 – inflammatory modulator
DMX-200 – inflammatory modulator For personal use only A CCR2 inhibitor working synergistically alongside the current standard of care (AT1R blocker): G protein-coupled receptor (GPCR) Commercial manufacturing sites established in USA3 1. ASX release and investor presentation 29Jul20 and ASX release
Slide 21: DMX-200: unique pharmacology
DMX-200: unique pharmacology • CCR2 activation promotes recruitment of inflammatory 500 Proteinuria (mg/24hours) monocytes to the kidney 400 For personal use only 300 DMX-200 inhibits CCR21 200 Simultaneous inhibition of * CCR2 and AT1R reduces 100 proteinuria an important • Monocytes promote sclero
Slide 22: DMX-200 Phase 2 effect on inflammatory biomarker
DMX-200 Phase 2 effect on inflammatory biomarker1 Unlike other CCR2 antagonists investigated to date, treatment with DMX-200 reduces the urine concentration of the pro-inflammatory ligand of CCR2 called MCP-12 For personal use only Average baseline MCP-1 versus Change in MCP-1 over time on average b
Slide 23: Intellectual property portfolio
Intellectual property portfolio DMX-200 For personal use only Exclusivity Portfolio 3 7/10 years Exp.2042 Orphan exclusivity from (if granted) marketing approval date in many territories1 Portfolio 2 Formulation Portfolio 5 Global application3 + Exp.2042 Exp.2045/6 (if granted) Paediatric (if grante
Slide 24: Dimerix board
Dimerix board For personal use only Previous experience: Previous experience: Previous experience: Previous experience: Previous experience: (2) (1) (Faulding)(1) • Senior pharmaceutical executive • Experienced in product • Extensive biotech drug • Experienced executive in • Experienced technology a
Slide 25: Dimerix management
Dimerix management For personal use only Previous experience: Previous experience: Previous experience: Previous experience: (1) • Experienced in product • Experienced finance and • 35 years international experience • Experienced pharmaceutical development, commercial strategy governance executive w
Slide 26: Medical Advisory Board
Medical Advisory Board For personal use only Professor of Clinical Trials and Professor of Medicine & Mayer Professor of Renal An attending physician and Renal Physician and Head of Graduated from Haverford Assistant Professor in the Personalized Medicine: Molecular & Cellular Medicine: Department o